每经AI快讯，丝路视觉（SZ 300556，收盘价：18.24元）12月16日晚间发布公告称，截至本公告日，李 萌迪累计质押股数为675万股，占其所持股份比例为41.03%。 2025年1至6月份，丝路视觉的营业收入构成为：CG业务占比99.98%，其他业务占比0.02%。 截至发稿，丝路视觉市值为22亿元。 每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ （记者 曾健辉） ...

Group 1 - The company Silk Road Vision (SZ 300556) held its ninth board meeting of the fifth session on October 24, 2025, via telecommunication voting, discussing the proposal for the management system for senior executives' departure [1] - For the first half of 2025, Silk Road Vision's revenue composition was 99.98% from CG business and 0.02% from other businesses [1] - As of the report date, Silk Road Vision's market capitalization was 2.5 billion yuan [1] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - The secondary market for biomedicine is experiencing a boom, while the primary market is facing challenges in fundraising [1]

Group 1 - The core point of the news is that Silk Road Vision (SZ 300556) announced the completion of a share reduction plan by shareholders Ding Pengqing and Tian Wanjun, who collectively reduced approximately 130,000 shares, accounting for 0.107% of the company's total shares [1] - As of the latest report, Silk Road Vision has a market capitalization of 2.4 billion yuan [3] Group 2 - For the first half of 2025, Silk Road Vision's revenue composition shows that the CG business accounts for 99.98% of total revenue, while other businesses contribute only 0.02% [2]